Loading...

Amryt Pharma

ISE:AYP
Snowflake Description

Limited growth with worrying balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
AYP
ISE
£34M
Market Cap
  1. Home
  2. IE
  3. Pharmaceuticals & Biotech
Company description

Amryt Pharma plc, a commercial stage pharmaceutical company, focuses on the acquisition, development, and commercialization of medicines for the treatment of rare and orphan diseases. The last earnings update was 36 days ago. More info.


Add to Portfolio Compare Print
  • Amryt Pharma has significant price volatility in the past 3 months.
AYP Share Price and Events
7 Day Returns
-6.7%
ISE:AYP
1.9%
Europe Pharmaceuticals
-0%
IE Market
1 Year Returns
-
ISE:AYP
2%
Europe Pharmaceuticals
-13.6%
IE Market
AYP Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Amryt Pharma (AYP) -6.7% -6.7% -20% - -39.1% -
Europe Pharmaceuticals 1.9% 1.2% -4.6% 2% 3.3% 5%
IE Market -0% -5.3% 1.6% -13.6% 0.7% 39.8%
1 Year Return vs Industry and Market
  • No trading data on AYP.
  • No trading data on AYP.
Price Volatility
AYP
Industry
5yr Volatility vs Market

AYP Value

 Is Amryt Pharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Amryt Pharma is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Amryt Pharma has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Amryt Pharma. This is due to cash flow or dividend data being unavailable. The share price is €0.14.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Amryt Pharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Amryt Pharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ISE:AYP PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in EUR €-0.09
AIM:AMYT Share Price ** AIM (2019-05-20) in GBP £0.12
AIM:AMYT Share Price converted to EUR reporting currency Exchange rate (GBP/ EUR) 1.134 €0.14
Europe Pharmaceuticals Industry PE Ratio Median Figure of 43 Publicly-Listed Pharmaceuticals Companies 21.72x
Ireland Market PE Ratio Median Figure of 23 Publicly-Listed Companies 11.42x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Amryt Pharma.

ISE:AYP PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AIM:AMYT Share Price ÷ EPS (both in EUR)

= 0.14 ÷ -0.09

-1.5x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Amryt Pharma is loss making, we can't compare its value to the Europe Pharmaceuticals industry average.
  • Amryt Pharma is loss making, we can't compare the value of its earnings to the Ireland market.
Price based on expected Growth
Does Amryt Pharma's expected growth come at a high price?
Raw Data
ISE:AYP PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.5x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
Not available
Europe Pharmaceuticals Industry PEG Ratio Median Figure of 35 Publicly-Listed Pharmaceuticals Companies 1.83x
Ireland Market PEG Ratio Median Figure of 19 Publicly-Listed Companies 0.99x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Amryt Pharma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Amryt Pharma's assets?
Raw Data
ISE:AYP PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in EUR €-0.01
AIM:AMYT Share Price * AIM (2019-05-20) in GBP £0.12
AIM:AMYT Share Price converted to EUR reporting currency Exchange rate (GBP/ EUR) 1.134 €0.14
Europe Pharmaceuticals Industry PB Ratio Median Figure of 94 Publicly-Listed Pharmaceuticals Companies 2.96x
Ireland Market PB Ratio Median Figure of 33 Publicly-Listed Companies 1.15x
ISE:AYP PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AIM:AMYT Share Price ÷ Book Value per Share (both in EUR)

= 0.14 ÷ -0.01

-11.94x

* Primary Listing of Amryt Pharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Amryt Pharma has negative assets, we can't compare the value of its assets to the Europe Pharmaceuticals industry average.

Next steps:

  1. Take a look at our analysis of AYP’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Amryt Pharma's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Pharmaceuticals industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Amryt Pharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Amryt Pharma has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

AYP Future Performance

 How is Amryt Pharma expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
37.9%
Expected annual growth in revenue.
Earnings growth vs Low Risk Savings
Is Amryt Pharma expected to grow at an attractive rate?
  • Unable to compare Amryt Pharma's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Amryt Pharma's earnings growth to the Ireland market average as no estimate data is available.
  • Amryt Pharma's revenue growth is expected to exceed the Ireland market average.
Annual Growth Rates Comparison
Raw Data
ISE:AYP Future Growth Rates Data Sources
Data Point Source Value (per year)
ISE:AYP Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 37.9%
Europe Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 12.6%
Europe Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 4.6%
Ireland Market Earnings Growth Rate Market Cap Weighted Average 11.9%
Ireland Market Revenue Growth Rate Market Cap Weighted Average 5.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ISE:AYP Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ISE:AYP Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 56 1
2020-12-31 22 -9 2
2019-12-31 20 -20 2
ISE:AYP Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-12-31 14 -13 -26
2018-09-30 14 -12 -25
2018-06-30 14 -11 -24
2018-03-31 13 -11 -25
2017-12-31 13 -12 -26
2017-09-30 10 -11 -22
2017-06-30 7 -11 -18
2017-03-31 4 -8 -13
2016-12-31 1 -6 -8

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Amryt Pharma is high growth as no earnings estimate data is available.
  • Amryt Pharma's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ISE:AYP Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Amryt Pharma Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ISE:AYP Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31
2020-12-31
2019-12-31
ISE:AYP Past Financials Data
Date (Data in EUR Millions) EPS *
2018-12-31 -0.09
2018-09-30 -0.09
2018-06-30 -0.09
2018-03-31 -0.10
2017-12-31 -0.12
2017-09-30 -0.10
2017-06-30 -0.08
2017-03-31 -0.07
2016-12-31 -0.05

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Amryt Pharma will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Amryt Pharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Amryt Pharma has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

AYP Past Performance

  How has Amryt Pharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Amryt Pharma's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Amryt Pharma does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Amryt Pharma's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Amryt Pharma's 1-year growth to the Europe Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Amryt Pharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Amryt Pharma Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ISE:AYP Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 14.45 -25.78 15.36 9.05
2018-09-30 14.04 -24.74 14.44 9.25
2018-06-30 13.62 -23.69 13.52 9.45
2018-03-31 13.20 -24.92 12.28 10.00
2017-12-31 12.78 -26.14 11.05 10.56
2017-09-30 10.07 -21.83 8.89 8.84
2017-06-30 7.37 -17.52 6.73 7.11
2017-03-31 4.36 -12.66 5.50 4.73
2016-12-31 1.35 -7.80 4.27 2.34
2015-12-31 -3.58 0.20

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Amryt Pharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Amryt Pharma has efficiently used its assets last year compared to the Europe Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Amryt Pharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Amryt Pharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Amryt Pharma has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

AYP Health

 How is Amryt Pharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Amryt Pharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Amryt Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Amryt Pharma's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Amryt Pharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Amryt Pharma has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Amryt Pharma Company Filings, last reported 4 months ago.

ISE:AYP Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 -3.23 16.61 9.81
2018-09-30 -3.23 16.61 9.81
2018-06-30 10.85 11.05 12.21
2018-03-31 10.85 11.05 12.21
2017-12-31 21.89 10.60 20.51
2017-09-30 21.89 10.60 20.51
2017-06-30 19.52 10.25 10.94
2017-03-31 19.52 10.25 10.94
2016-12-31 33.04 0.00 8.27
2015-12-31 -1.19 2.48 0.72
  • Amryt Pharma has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Amryt Pharma's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Amryt Pharma has less than a year of cash runway based on current free cash flow.
  • Amryt Pharma has less than a year of cash runway if free cash flow continues to grow at historical rates of 38.8% each year.
X
Financial health checks
We assess Amryt Pharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Amryt Pharma has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

AYP Dividends

 What is Amryt Pharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Amryt Pharma dividends. Estimated to be 0% next year.
If you bought €2,000 of Amryt Pharma shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Amryt Pharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Amryt Pharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ISE:AYP Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 32 Stocks 3.4%
Ireland Market Average Dividend Yield Market Cap Weighted Average of 21 Stocks 2.4%
Ireland Minimum Threshold Dividend Yield 10th Percentile 1.2%
Ireland Bottom 25% Dividend Yield 25th Percentile 2.2%
Ireland Top 25% Dividend Yield 75th Percentile 4.1%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ISE:AYP Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Amryt Pharma has not reported any payouts.
  • Unable to verify if Amryt Pharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Amryt Pharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Amryt Pharma has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Amryt Pharma's dividends in 3 years as they are not expected to pay a notable one for Ireland.
X
Income/ dividend checks
We assess Amryt Pharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Amryt Pharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Amryt Pharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

AYP Management

 What is the CEO of Amryt Pharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Joe Wiley
COMPENSATION €567,000
AGE 47
CEO Bio

Dr. Joseph Wiley, also known as Joe, M.D. is the Founder of Amryt Pharma plc and serves as its Chief Executive Officer. Dr. Wiley has over 20 years of experience in the pharmaceutical, medical and venture industries. Dr. Wiley served as a Principal of Sofinnova Ventures, Inc. Dr. Wiley joined Sofinnova Ventures in 2012 and was responsible for sourcing, evaluating and supporting the team’s investments in Ireland. He opened and led Sofinnova Ventures' European office. Dr. Wiley served as a Senior Investment Manager, Private Equity at Maven Capital Partners UK LLP and White Rose Technology Seedcorn Fund. He was employed at Inventages Venture Capital Investment Inc. He served as the Head of Healthcare and Investment Director at Synova Capital LLP, where he joined in March 2010. He served as a Medical Director at Astellas Pharma, where he focused on transplant, urology and pain. Dr. Wiley served as an Associate Director at Spirit Capital Partners LLP. He had responsibility for origination initiatives in the Midlands and a specific focus on the healthcare sector. Dr. Wiley served as a Senior Investment Manager of Private Equity at Aberdeen Asset Managers Private Equity Ltd., where he joined in February 2005. Dr. Wiley managed the White Rose Fund and was also responsible for its investments in EDSR Holdings Limited and Enpure Holdings Limited. He was responsible for investments in Celltran Limited, Syntopix Limited and Pro-Cure Therapeutics Ltd. Dr. Wiley spent at a year at Inventages Venture Capital in Geneva, where he was responsible for making early stage investments in life sciences and biotechnology companies. He worked in clinical medicine as a practicing Neurologist and has published in Neurogenetics. Dr. Wiley serves as a Director of Axordia Limited, Asterion Limted and Enpure Holdings Limited. He has been a Director at Amryt Pharma plc since April 19, 2016. He served as an Independent Director at Innocoll Holdings plc (formerly known as Innocoll AG) from March 16, 2016 to July 24, 2017. Dr. Wiley served as Member of Supervisory Board of Innocoll since December 2014 until March 16, 2016. He is a Member of the Royal College of Physicians in Ireland. Dr. Wiley is a Chief Investigator in a number of pharmaceutical clinical trials. He conducted Parkinson’s Disease research at the Mayo Clinic and was published in many scientific journals, including Neurology and Movement Disorders. Dr. Wiley graduated with an M.B.A. from INSEAD and has a Degree in Medicine specializing in Neurology from The University of Dublin, Trinity College.

CEO Compensation
  • Joe's compensation has increased whilst company is loss making.
  • Joe's remuneration is higher than average for companies of similar size in Ireland.
Management Team Tenure

Average tenure and age of the Amryt Pharma management team in years:

2.4
Average Tenure
50
Average Age
  • The tenure for the Amryt Pharma management team is about average.
Management Team

Joe Wiley

TITLE
Founder
COMPENSATION
€567K
AGE
47

Rory Nealon

TITLE
CFO, COO
COMPENSATION
€459K
AGE
50
TENURE
16.3 yrs

Tobias Zahn

TITLE
Head of Clinical Operations

Mark Sumeray

TITLE
Chief Medical Officer
AGE
52
TENURE
2.7 yrs

David Allmond

TITLE
Chief Commercial Officer
TENURE
2.2 yrs

Derval O'Carroll

TITLE
Head of Regulatory Affairs
TENURE
1.3 yrs

Jordi Casals

TITLE
Head of Europe

Helen Phillips

TITLE
Head of Medical Affairs
Board of Directors Tenure

Average tenure and age of the Amryt Pharma board of directors in years:

3.1
Average Tenure
52
Average Age
  • The tenure for the Amryt Pharma board of directors is about average.
Board of Directors

Harry Stratford

TITLE
Non-Executive Chairman
COMPENSATION
€80K
AGE
70

Joe Wiley

TITLE
Founder
COMPENSATION
€567K
AGE
47
TENURE
3.1 yrs

Rory Nealon

TITLE
CFO, COO
COMPENSATION
€459K
AGE
50
TENURE
3.1 yrs

James Culverwell

TITLE
Senior Non-Executive Director
COMPENSATION
€57K
TENURE
2.2 yrs

Alan Harris

TITLE
Head of Scientific Advisory Board
AGE
67

Ray Stafford

TITLE
Non-Executive Director
COMPENSATION
€44K
TENURE
3.1 yrs

Markus Ziener

TITLE
Non-Executive Director
COMPENSATION
€44K
AGE
52
TENURE
2.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Amryt Pharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Amryt Pharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

AYP News

Simply Wall St News

AYP Company Info

Description

Amryt Pharma plc, a commercial stage pharmaceutical company, focuses on the acquisition, development, and commercialization of medicines for the treatment of rare and orphan diseases. The company operates through two segments, Commercial and Research and Development. It offers Lojuxta (lomitapide), a drug used to treat a rare life-threatening disease Homozygous Familial Hypercholesterolaemia; and a range of dermo cosmetic products under the Imlan brand. Its products in development includes AP101 (Oleogel-S10), a prescription medicine used for the treatment of partial-thickness wounds in adults, which is in Phase III clinical trial; and AP102, a somatostatin analogue peptide medicine, which is in pre-clinical stage for patients with rare neuoendocrine diseases, such as acromegaly; and AP103, a gene therapy product line. The company operates in European Economic Area, the Middle East, North Africa, Turkey, Israel, and Switzerland. Amryt Pharma plc is based in London, the United Kingdom.

Details
Name: Amryt Pharma plc
AYP
Exchange: ISE
Founded:
£38,569,734
274,817,283
Website: http://www.amrytpharma.com
Address: Amryt Pharma plc
Dept 920A,
196 High Road,
London,
Greater London, N22 8HH,
United Kingdom
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AIM AMYT Ordinary Shares London Stock Exchange AIM Market GB GBP 22. Feb 2016
DB AYP Ordinary Shares Deutsche Boerse AG DE EUR 22. Feb 2016
ISE AYP Ordinary Shares Irish Stock Exchange IE EUR 22. Feb 2016
Number of employees
Current staff
Staff numbers
41
Amryt Pharma employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/23 00:17
End of day share price update: 2019/05/20 00:00
Last estimates confirmation: 2019/05/21
Last earnings filing: 2019/04/17
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.